OptimizeRx Corp
OPRX- Exchange
- Nasdaq
- Industry
- Services-Business Services, NEC
- SEC CIK
- 0001448431
No open-market purchases or sales by OptimizeRx Corp insiders were filed in the last 90 days; 112 institutions reported holding it in 13F filings for Q2 2026, worth $64.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −15 vs. previous quarter
- 112
- 13F valueReported value at the end of Q2 2026
- $64.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding OPRX, Q2 2026
No superinvestor reported holding OPRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by OptimizeRx Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 7, 2025 (view filing) | Oct 3 | 4 days | Silvestro Stephen LChief Executive Officer | SSale | −1.62K | $18.75 | −$30.4K | −0.9%188.9K after | |
| Sep 11, 2025 (view filing) | Aug 28 | 14 daysLate | Spangler Patrick DDirector | SSale | −11.1K | $17.49 | −$194.5K | −20.1%44.2K after | |
| Mar 19, 2025 (view filing) | Mar 14 | 5 daysLate | Lang James PaulDirector | PPurchase | +321.4K | $7.60 | +$2.44M | +472.4%389.5K after | |
| Dec 16, 2024 (view filing) | Dec 12 | 4 days | Febbo William JCEO | PPurchase | +20.0K | $5.01 | +$100.2K | +3.4%601.3K after | |
| Jan 11, 2024 (view filing) | Jan 9 | 2 days | Odence-Ford MarionGeneral Counsel and CCO | SSale | −4.00K | $15.19 | −$60.8K | −26.5%11.1K after | 10b5-1 |
| Aug 30, 2022 (view filing) | Aug 26 | 4 days | Odence-Ford MarionGeneral Counsel and CCO | PPurchase | +1.00K | $15.75 | +$15.8K | +25.0%5.00K after | |
| Aug 23, 2022 (view filing) | Aug 19 | 4 days | Lang James PaulDirector | PPurchase | +6.00K | $16.45 | +$98.7K | +18.4%38.7K after | |
| Aug 23, 2022 (view filing) | Aug 19-22 | 4 days | Febbo William JCEO | PPurchase | +16.1K | $15.59 | +$251.0K | +3.6%461.8K after | 2 lots |
| Aug 17, 2022 (view filing) | Aug 16 | 1 day | Silvestro Stephen LCCO | PPurchase | +3.20K | $15.66 | +$50.1K | New position3.20K after | |
| Aug 17, 2022 (view filing) | Aug 15 | 2 days | Stelmakh EdwardCFO/COO | PPurchase | +3.00K | $15.43 | +$46.3K | New position3.00K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in OptimizeRx Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Whetstone Capital Advisors, LLC | 1,508,303 | $8.63M | 2.29% | 00.0% | Unchanged |
| Royce & Associates LP | 1,089,398 | $6.23M | 0.05% | +201,368+22.7% | Added |
| Vanguard Capital Management LLC | 699,604 | $4.00M | 0.00% | +14,155+2.1% | Added |
| Kennedy Capital Management, Inc. | 644,150 | $3.68M | 0.07% | −12,108−1.8% | Reduced |
| Rice Hall James & Associates, LLC | 633,842 | $3.63M | 0.18% | +31,921+5.3% | Added |
| Blair William & Co | 607,925 | $3.48M | 0.01% | −7,067−1.1% | Reduced |
| AQR Capital Management LLC | 583,956 | $3.34M | 0.00% | +369,002+171.7% | Added |
| Dimensional Fund Advisors LP | 477,687 | $2.73M | 0.00% | −85,883−15.2% | Reduced |
| BlackRock, Inc. | 445,382 | $2.55M | 0.00% | −718,119−61.7% | Reduced |
| Parkman Healthcare Partners LLC | 350,347 | $2.00M | 0.21% | −379,022−52.0% | Reduced |